Clinical Trial News and Research

RSS

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Meda presents new positive results from a Phase-III clinical trial of Dymista at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey.

15 Jun 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.

15 Jun 2011

DePuy Orthopaedics receives FDA approval for ceramic-on-metal total artificial hip system

The U.S. Food and Drug Administration approved on June 13 the first ceramic-on-metal total artificial hip system for patients with osteoarthritis.

15 Jun 2011

DATATRAK adds Research Dynamics to Connect Partner Program

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the addition of Research Dynamics Consulting Group LTD to its Connect Partner Program.

14 Jun 2011

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent was also shown to be more effective than a bare-metal stent, with equivalent safety.

14 Jun 2011

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes.

14 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

CTI completes pixantrone NDA resubmission meeting with FDA's Division of Oncology Drug Products

Cell Therapeutics, Inc. today announced that it met with the U.S. Food and Drug Administration's Division of Oncology Drug Products.

14 Jun 2011

FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer

The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of a new technology: Cornell Dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

13 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the primary endpoint of glucose disposition index did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale.

10 Jun 2011

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

Patheon second quarter revenues decrease 3.1% to $170.0 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today financial results for the second quarter ended April 30, 2011.

10 Jun 2011

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

10 Jun 2011

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.

10 Jun 2011

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Emergent BioSolutions Inc. announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).

10 Jun 2011

ASI announces successful completion of $10 million round of financing

Access Scientific, Inc. (ASI) today announced the successful completion of a $10 million round of financing. The round was led by CAC and further supported by the company's previous institutional investors.

9 Jun 2011

Clinical Trial News and Research

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

DePuy Orthopaedics receives FDA approval for ceramic-on-metal total artificial hip system

DATATRAK adds Research Dynamics to Connect Partner Program

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

CTI completes pixantrone NDA resubmission meeting with FDA's Division of Oncology Drug Products

FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Larger trial study needed to decide fate of niacin

Patheon second quarter revenues decrease 3.1% to $170.0 million

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

ASI announces successful completion of $10 million round of financing

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer